Sarah McCurdy, MBA – Chief Executive Officer, Board Manager
Ms. McCurdy has over 25 years of experience in the Life Sciences as a researcher and executive with expertise in product development, commercialization, and Business Unit Leadership in Biotechnology, Genomics, and Medical Devices. Ms. McCurdy was an early employee at Gilead Sciences heading up Gilead's Antisense oligonucleotide production effort. At Lynx Therapeutics and Applied Biosystems, she held increasing roles of leadership for the development and commercialization of automated instrumentation for the synthesis and sequencing of DNA and proteins.
Most recently she held senior executive leadership roles at W.L Gore®, a medical device company focusing on the development and commercialization of products for Neurology, Cardiology and Stroke treatment. While there, she led the commercialization of multiple Gore medical devices. Ms. McCurdy also led a number of transactions related to technology, product and company acquisitions. Her expertise includes leading global development and commercialization efforts as well as operations in highly regulated markets.
Ms. McCurdy received her B.S in Chemistry from Northern Arizona University and her MBA from Santa Clara University.
Laurie Goodman, PhD, Chief Scientific Officer
Dr. Goodman brings more than 25 years experience with innovative technology development, clinical cancer diagnostics, and translational cancer research within the biotechnology industry. She has held broad senior level roles encompassing research and development as well as clinical and medical affairs. Most recently she held the position of Senior Director of Scientific and Medical Affairs for Biodesix, an innovator of blood-based cancer diagnostics. She was instrumental in building and leading the company's first scientific and medical affairs team as well initiating/leading key academic collaborations in the areas of lung and breast cancer. Other senior level roles included directing the analytic team involved in the CLIA validation and commercialization of Monogram Biosciences first oncology diagnostic product, HERmark®. Following a postdoctoral fellowship at Genentech, she began her career at Lynx Therapeutics (currently Illumina) where she initiated and developed a breast cancer scientific program to validate the company's next generation sequencing platform.
Dr. Goodman is an author on several key publications and patents related to analytic and clinical cancer biomarkers. She holds a BS degree in Biology with a minor in Chemistry from Arizona State University and a PhD in Cell and Molecular Biology from University of California Berkeley.
Karl Deisseroth, MD, PhD, Founder
Karl Deisseroth is the D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University, and Investigator of the Howard Hughes Medical Institute. He received his undergraduate degree from Harvard, his PhD from Stanford, and his MD from Stanford; he also completed postdoctoral training, medical internship, and adult psychiatry residency at Stanford, and he is board-certified by the American Board of Psychiatry and Neurology. He continues as a practicing psychiatrist at Stanford with specialization in affective disorders and autism-spectrum disease, employing medications along with neural stimulation.
Over a period of twelve years, his laboratory created and developed optogenetics, CLARITY, and a broad range of supportive and enabling methods. He also has employed his technologies to discover the neural cell types and connections that cause adaptive and maladaptive behaviors, and has disseminated the technologies to thousands of laboratories around the world.
For his discoveries, Deisseroth has received the NIH Director's Pioneer Award (2005), the Zuelch Prize (2012), the Perl Prize (2012), the BRAIN prize (2013), the Pasarow Prize (2013), the Breakthrough Prize (2015) and the BBVA Award (2016), and among other honors, was the sole recipient for optogenetics of the 2010 Koetser Prize, the 2010 Nakasone Prize, the 2011 Alden Spencer Prize, the 2013 Richard Lounsbery Prize, the 2014 Dickson Prize in Science, the 2015 Keio Prize, the 2015 Lurie Prize, the 2015 Albany Prize, and the 2015 Dickson Prize in Medicine. He was selected a Howard Hughes Medical Institute Investigator in 2013, and was elected to the US National Academy of Medicine in 2010 and to the US National Academy of Sciences in 2012.
ClearLight Diagnostics Board Members
Alex Wiegers – Board Manager
Wiegers Capital Partners, Co-Founder and Managing Partner
Mr. Wiegers, co-founder and managing partner, is responsible for the daily management of WCP and its investment activities. He currently represents WCP's interests on the boards of Hart Energy Publications and AL George LLC and participates in the financial management and development of its investments. Prior to WCP, Mr. Wiegers was an associate of Western Growth Capital, an institutional private equity fund, where he was involved in the financing and corporate development of Mountainsmith LLC and Qdoba LLC. Mr. Wiegers has a BA from the University of Colorado.
John Snyder, MD – Board Manager
Snyder Family Foundation
Dr. Snyder is a retired surgeon who currently manages research for the Snyder Family Foundation. He and the foundation's research committee seek out investigators to support scholarships and biomedical studies that delve into the complexities of diseases. The foundation has evolved from providing lab facilities for hospitals to supporting investigators such as Stanford's Judith Shizuru, PhD '86, MD '92; Karl Deisseroth, PhD '98, MD '00; and Seung Kim, MD/PhD '92, with the hope of raising their chances to glean the next level of research support.